Key result
Review outlines current diagnostic and treatment strategies for ARVD.
Why the study?
Screening of known genes identifies mutations in only 60–65% of patients with arrhythmogenic right ventricular dysplasia, presenting challenges in genotype-specific diagnostics and prompt treatment.
Current genetic screening identifies mutations in only 60-65% of patients with ARVD, highlighting challenges in genotype-specific diagnostics.
Negative genetic results do not exclude ARVD; leaves open the need for improved diagnostics and protocols.
Actually the screening of all the known genes allows identifying mutations only in 60– 65% patients with arrhythmogenic right ventricular dysplasia. This review analyses domestic and foreign studies on this issue on a basis of long-term observation. The materials presented demonstrate problems of the genotype-specific diagnostics and prompt treatment of the patients with this disease
No takes yet. Share an insight, caveat, or question.
EVDOKIMOV et al. (2025) conducted a review in Patients with arrhythmogenic right ventricular dysplasia. This paper is a literature review on the diagnostics and treatment of arrhythmogenic right ventricular dysplasia without presenting original clinical trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: